Summit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trialtranslating…

After an interim overall survival result last year that shook investor confidence, Akeso has claimed victory Thursday with updated China-only Phase 3 data for its closely watched PD-1xVEGF bispecific in certain lung cancer patients. Akeso ...

Sign in to join the discussion.

Loading comments…